{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=22",
    "query": {
      "condition": "Double Blind",
      "page": 22
    },
    "page_size": 10
  },
  "pagination": {
    "page": 22,
    "page_size": 10,
    "total_count": 18300,
    "total_pages": 1830,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=23&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Double+Blind&page=21&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-18T19:46:00.588Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03294538",
      "title": "Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrophic Vaginitis"
      ],
      "interventions": [
        {
          "name": "Generic Estradiol Vaginal Cream USP, 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Estrace® Vaginal Cream USP, 0.01%",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Vaginal Cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "75 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 75 Years · Female only"
      },
      "enrollment_count": 663,
      "start_date": "2016-05-18",
      "completion_date": "2017-02-15",
      "has_results": true,
      "last_update_posted_date": "2019-12-26",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 44,
      "location_summary": "Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03294538"
    },
    {
      "nct_id": "NCT00639158",
      "title": "Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the Blood",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemias",
        "Coronary Heart Disease",
        "Combined (Atherogenic) Dyslipidemia",
        "Mixed Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "ABT-335",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 543,
      "start_date": "2008-02",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2011-06-13",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 118,
      "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Hueytown, Alabama + 107 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Hueytown",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00639158"
    },
    {
      "nct_id": "NCT00631878",
      "title": "Safety and Pharmacokinetics Study in VLBW Neonates With BSYX-A110",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Neonatal Staphylococcal Sepsis"
      ],
      "interventions": [
        {
          "name": "Pagibaximab (formerly BSYX-A110)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biosynexus Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Days",
        "maximum_age": "7 Days",
        "sex": "ALL",
        "summary": "3 Days to 7 Days"
      },
      "enrollment_count": 53,
      "start_date": "2001-11",
      "completion_date": "2003-08",
      "has_results": false,
      "last_update_posted_date": "2008-03-10",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00631878"
    },
    {
      "nct_id": "NCT04210115",
      "title": "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Esophageal Squamous Cell Carcinoma (ESCC)",
        "Gastroesophageal Junction Carcinoma (GEJC)",
        "Esophageal Adenocarcinoma (EAC)"
      ],
      "interventions": [
        {
          "name": "pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "5-FU",
          "type": "DRUG"
        },
        {
          "name": "radiotherapy",
          "type": "RADIATION"
        },
        {
          "name": "leucovorin",
          "type": "DRUG"
        },
        {
          "name": "levoleucovorin",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 703,
      "start_date": "2020-02-28",
      "completion_date": "2026-06-26",
      "has_results": false,
      "last_update_posted_date": "2026-10-30",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 19,
      "location_summary": "Long Beach, California • Columbus, Georgia • Westwood, Kansas + 16 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04210115"
    },
    {
      "nct_id": "NCT05158335",
      "title": "Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "MBX 2109 (Part A)",
          "type": "DRUG"
        },
        {
          "name": "MBX 2109 (Part B)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MBX Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "21 Years to 60 Years"
      },
      "enrollment_count": 76,
      "start_date": "2021-11-10",
      "completion_date": "2023-06-20",
      "has_results": false,
      "last_update_posted_date": "2023-08-09",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05158335"
    },
    {
      "nct_id": "NCT00782535",
      "title": "Safety and Efficacy Study of Treatment With Single Doses of CHF 4226 pMDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "CHF 4226 pMDI",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chiesi Farmaceutici S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 20,
      "start_date": "2008-12",
      "completion_date": "2009-03",
      "has_results": false,
      "last_update_posted_date": "2019-11-06",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 5,
      "location_summary": "DeLand, Florida • Madisonville, Kentucky • Cincinnati, Ohio + 2 more",
      "locations": [
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Madisonville",
          "state": "Kentucky"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Spartanburg",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00782535"
    },
    {
      "nct_id": "NCT00785135",
      "title": "Effects of Prismatic Spectacle Lenses on Symptoms of Dizziness, Headache and Anxiety as Caused by Vertical Heterophoria",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Binocular Dysfunction",
        "Vertical Heterophoria",
        "Vision, Binocular",
        "Vision Disparity"
      ],
      "interventions": [
        {
          "name": "Lenses containing prismatic correction",
          "type": "DEVICE"
        },
        {
          "name": "Lenses not containing prismatic correction",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Vision Specialists of Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "14 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2008-11",
      "completion_date": "2015-11",
      "has_results": false,
      "last_update_posted_date": "2020-10-12",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 1,
      "location_summary": "Birmingham, Michigan",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00785135"
    },
    {
      "nct_id": "NCT00888940",
      "title": "Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bloodloss",
        "Surgical Procedures, Operative"
      ],
      "interventions": [
        {
          "name": "Ecallantide",
          "type": "DRUG"
        },
        {
          "name": "Cyklokapron(R)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 243,
      "start_date": "2009-06",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2015-08-10",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00888940"
    },
    {
      "nct_id": "NCT01597050",
      "title": "Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lupus Erythematosus, Discoid",
        "Lupus Erythematosus, Systemic"
      ],
      "interventions": [
        {
          "name": "R932333",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Rigel Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 54,
      "start_date": "2012-08",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2016-07-14",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 12,
      "location_summary": "Los Angeles, California • Redwood City, California • South Bend, Indiana + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Redwood City",
          "state": "California"
        },
        {
          "city": "South Bend",
          "state": "Indiana"
        },
        {
          "city": "Lake Success",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597050"
    },
    {
      "nct_id": "NCT04829214",
      "title": "OTO-313 in Subjects With Unilateral Subjective Tinnitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Subjective Tinnitus"
      ],
      "interventions": [
        {
          "name": "OTO-313",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otonomy, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 153,
      "start_date": "2021-03-22",
      "completion_date": "2022-06-30",
      "has_results": true,
      "last_update_posted_date": "2023-01-06",
      "last_synced_at": "2026-11-18T19:46:00.588Z",
      "location_count": 31,
      "location_summary": "Fresno, California • Torrance, California • Aurora, Colorado + 26 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Boynton Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04829214"
    }
  ]
}